Single-target cancer drugs can teach tumors how to route around them. Faeth’s answer is PIKTOR - two oral medicines, three pathway nodes and a public-company-sized test of whether deeper blockade can stay tolerable.
Most antibody-drug conjugates carry one weapon. Callio is testing whether two coordinated payloads on the same HER2-targeted carrier can make resistant tumors run out of exits.